UK Radiotherapy Market Report 2022 to 2030

UK Radiotherapy Market Analysis

$ 3999

By 2030, it is anticipated that the UK Radiotherapy Market will reach a value of $7.7 Bn from $4.7 Bn in 2022, growing at a CAGR of 6.4% during 2022-30. The Radiotherapy Therapeutics Market in the UK is dominated by a few domestic players such as Alpha Omega Services, Curium Pharma, and Oncology Systems Limited. The radiotherapy market in the UK is segmented into different types, technology, procedures, application, and end-user. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives and reimbursement policy. The demand for UK Radiotherapy is increasing on account of the rise in cancer cases in the country.

ID: IN10GBPH043 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Dr. Vishwa Modhia

Buy Now

UK Radiotherapy Market Analysis Summary

By 2030, it is anticipated that the UK Radiotherapy Market will reach a value of $7.7 Bn from $4.7 Bn in 2022, growing at a CAGR of 6.4% during 2022-30.

The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. There are around 375,000 new cancer cases in the UK every year, that is around 1,000 every day (2016-2018). Breast, prostate, lung and bowel cancers together accounted for over half (53 %) of all new cancer cases in the UK in 2016-2018. Radiotherapy UK is a non-profit organisation dedicated to ensuring that the best radiotherapy treatment is provided throughout the United Kingdom.

The United Kingdom is currently experiencing an unprecedented cancer crisis as a result of a lethal mix of catastrophic wait times and a lack of capacity in critical services like as radiation. This cancer catastrophe is unfolding at a time when technological improvements in radiation provide so many opportunities. UK's government spent 12 % of its GDP on healthcare in 2020.

UK Radiotherapy Market Analysis

Market Dynamics

Market Growth Drivers Analysis

According to current estimates, one in every two persons in the UK will develop cancer, and one in every four will require radiation treatment at some point in their lives. Radiotherapy is required for 40 % of cancer cures and 50 % of cancer patients. In the last ten years, there has been a digital revolution, accelerated by Covid, that has produced low-risk, high-tech, digital solutions that can be implemented immediately and have the potential to transform radiotherapy services and cancer infrastructure, support the workforce, help deal with the backlog, and improve cancer survival both now and in the future. These aspects could boost UK Radiotherapy Market.

Market restraints

Because of limited resources, technical improvements that assist cancer patients in other nations are not readily available in the UK. The startling budget shortfall is one of several reasons why the UK ranks towards the bottom of international cancer survival tables. As a result of COVID-19, half of cancer patients are waiting more than 62 days for their initial radiotherapy treatment. These factors may deter new entrants into the UK Radiotherapy Market.

Competitive Landscape

Key Players

Alpha Omega Services: A UK-based company that provides radiation protection and quality assurance equipment and services for medical and industrial applications.
Curium Pharma: A UK-based company that provides radiopharmaceuticals for diagnostic and therapeutic applications, including cancer treatment.
Oncology Systems Limited: A UK-based company that provides radiotherapy equipment, including linear accelerators, brachytherapy devices, and treatment planning systems.
Xstrahl: A UK-based company that provides advanced radiation therapy solutions, including superficial and orthovoltage systems, as well as a range of research applications.
RTsafe: A UK-based company that provides patient-specific quality assurance tools for radiation therapy treatment planning and delivery.
Precision Dose: A UK-based company that provides calibration and quality assurance equipment and services for radiation therapy applications

Recent Notable Updates

March 2023: The annual general meeting of the All-Party Parliamentary Group for Radiotherapy (APPG-RT) was very successful and interesting (AGM). Parliamentarians heard from prominent clinicians and Radiotherapy UK about the impact of the cancer backlog on services across the country, as well as how modest investments in radiotherapy technology, equipment, and people might help increase cancer survival.

Healthcare Policies and Reimbursement Scenarios

The Care Quality Commission (CQC) is responsible for regulating all healthcare providers in England, including those providing radiotherapy services. The Ionising Radiation (Medical Exposure) Regulations (IR(ME)R) set out the legal requirements for the use of ionising radiation in medical practice in the UK. The National Institute for Health and Care Excellence (NICE) provides guidance on the use of radiotherapy for specific cancers and other conditions. Radiotherapy is funded by the National Health Service (NHS) in the UK, which provides free healthcare to all UK residents. Radiotherapy is also funded by private medical insurance, which is an optional form of healthcare coverage that individuals can purchase.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Radiotherapy Segmentation

By Type (Revenue, USD Billion):

External Beam Radiation Therapy
Linear Accelerators
Compact Advanced Radiotherapy Systems
Cyberknife
Gamma Knife
?Tomotherapy
Proton Therapy
Cyclotron
?Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Radiation Therapy
?Others

?By Technology (Revenue, USD Billion):

External Beam Radiotherapy
Intensity-Modulated Radiation Therapy (IMRT)
Image-Guided Radiation Therapy (IGRT)
Stereotactic Radiation Therapy (SRT)
3D Conformal Radiation Therapy (3D-CRT)
Particle Therapy
Internal Beam Radiotherapy
Brachytherapy
High-Dose Rate Brachytherapy
Low-Dose Rate Brachytherapy
Image-Guided Brachytherapy
Pulse-Dose Rate Brachytherapy
Systemic Radiation Therapy
Intravenous Radiotherapy
Oral Radiotherapy?

By Application (Revenue, USD Billion):

Breast Cancer
Cervical Cancer
Colon and rectum Cancers
Stomach Cancer
Lung Cancer
Prostate Cancer
Skin Cancer
Liver Cancer
Other types of cancer

By End User (Revenue, USD Billion):

Hospitals
Radiotherapy Centers & Ambulatory Surgery Centers
?Cancer Research Institutes

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.